Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary InterventionResults of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial
Germano Di Sciascio, MD*,*,
Giuseppe Patti, MD*,
Vincenzo Pasceri, MD ,
Achille Gaspardone, MD ,
Giuseppe Colonna, MD and
Antonio Montinaro, MD
* Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Rome, Italy
Interventional Cardiology Unit, San Filippo Neri Hospital of Rome, Rome, Italy
Cardiology Unit, Sant'Eugenio Hospital of Rome, Rome, Italy
Interventional Cardiology Unit, Vito Fazzi Hospital of Lecce, Lecce, Italy
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Study Design of the ARMYDA-RECAPTURE Trial
Flow chart shows the design of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. angio = angiography; CK-MB = creatine kinase-myocardial band; Hs-CRP = high-sensitivity C-reactive protein; MI = myocardial infarction; NSTE-ACS = non–ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; TVR = target vessel revascularization.
|
|
View larger version (6K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Secondary End Points
Incidence of major adverse cardiac events at 30 days according to clinical presentation (stable angina vs. acute coronary syndrome). ACS = acute coronary syndrome.
|
|
View larger version (6K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Odds Ratio for 30-Day Major Adverse Cardiac Events
Results of multivariable analysis showing 50% major adverse cardiac events risk reduction at 30 days with atorvastatin (p = 0.039). Log axis has been used to present the odds ratios. LVEF = left ventricular ejection fraction.
|
|
|
